Important advances in HIV prevention research were announced recently at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), convened by IAS – the International AIDS Society.
Highlights included findings from a pair of trials evaluating whether infusions with a broadly neutralising antibody (bNAb) can prevent HIV acquisition and positive interim results from a study of long-acting injectable pre-exposure prophylaxis (PrEP) in women.
Other announcements included promising data from a study of islatravir as a once-monthly PrEP pill, a study warning that many African countries are not on track to meet key UNAIDS prevention targets, new data on global uptake of PrEP, and a promising new method to induce bNAbs that could help speed HIV vaccine development.
"COVID-19 has disrupted research around the world, so it's especially exciting to see this new progress," said IAS President Adeeba Kamarulzaman. "These research advances on options like broadly neutralising antibodies and injectable PrEP could help significantly strengthen our HIV prevention toolkit."